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Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder, the development
of which is regulated by several environmental and genetic risk factors. Two factors
theorized to contribute to the initiation and/or progression of AD pathogenesis are
age-related increases in inflammation and obesity. These factors may be particularly
problematic in women. The onset of menopause in mid-life elevates the vulnerability of
women to AD, an increased risk that is likely associated with the depletion of estrogens.
Menopause is also linked with an abundance of additional changes, including increased
central adiposity and inflammation. Here, we review the current literature to explore the
interactions between obesity, inflammation, menopause and AD.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative disease that is the leading
cause of dementia. The causal factor(s) that drives development and progression of the
disease is still debated, though the primary agents are likely β-amyloid protein (Aβ) and
the microtubule associated protein tau (LaFerla, 2010; Morris et al., 2014). Aβ is a small,
soluble peptide normally found at low levels in brain and bodily fluids. Increased production
and/or decreased clearance of Aβ fosters its inherent ability to self-associate into neurotoxic
oligomeric forms that become deposited in the brain parenchyma as plaques and in the
cerebrovasculature as cerebral amyloid angiopathy (Mucke and Selkoe, 2012). Interestingly,
genetic mutations that underlie familial AD yield increased Aβ production or its propensity
to aggregate (Tanzi, 2012). Thus, given both the toxic nature of Aβ and its genetic
links to the disease, Aβ accumulation is widely theorized to be the key regulator of AD
pathogenesis (Hardy and Higgins, 1992; Hardy, 2006). However, increasing evidence indicates
an essential role of tau, which undergoes hyperphosphorylation resulting in the formation of
neurofibrillary tangles, a hallmark of AD neuropathology found in many dead and dying
neurons (Iqbal et al., 2010). Emerging evidence indicates that tau, like Aβ, can be a potent
pathogenic protein and that it is capable of spreading pathology in a prion-like manner
(Bloom, 2014; Zempel and Mandelkow, 2014).
AD is more than just the accumulation of oligomeric and fibrillar Aβ and abnormally
phosphorylated tau. The disease is characterized by many pathologic changes, including
hypometabolism (Mosconi et al., 2008; Yao et al., 2011), blood-brain-barrier (BBB) disruption
(Zlokovic, 2011), and glial activation (Mrak and Griffin, 2005; Prokop et al., 2013). Sporadic
AD, which is not driven by the genetic mutations in familial AD and represents the
vast majority of cases, is likely to reflect the interactive effects of normal aging with
numerous environmental risk factors and subtle genetic polymorphisms. In turn, these
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interactions cooperatively disrupt pathways that regulate Aβ,
tau, and other AD pathologies. Thus, unraveling AD risk,
and perhaps developing successful prevention and intervention
strategies, will require understanding the interactions between
aging and a set of risk factors.
Two important AD risk factors are obesity and inflammation.
Obesity has increased at an alarming rate across westernized
countries, with approximately 70% of the US adult population
currently classified as either overweight or obese (Ogden et al.,
2014). Elevated adiposity increases the risks of numerous
conditions, including metabolic syndrome (McGill, 2014),
hypertension (Rahmouni, 2014), cardiovascular disease (Rocha
and Libby, 2009), and AD (Jayaraman and Pike, 2014). One
consequence of obesity that may underlie its pathogenic roles
is chronic inflammation, which is observed both in brain
and systemically. Inflammation is independently associated
with AD and numerous other age-related disorders (Michaud
et al., 2013; Bettcher and Kramer, 2014). A wealth of genetic,
epidemiological, and experimental findings identifies pro-
inflammatory pathways as significant regulators of various AD
pathologies (Wyss-Coray and Rogers, 2012). Interestingly, risk
factors can affect men and women differently. For example, the
apolipoprotein E ε4 allele (ApoE4), the most significant genetic
risk factor for late-onset AD, affects women much more strongly
than men (Altmann et al., 2014). The enhanced vulnerability of
aging women to some conditions, including increased risk of
osteoporosis, cardiovascular disease and perhaps AD, is related
to depletion of estrogens at menopause. Here, we consider the
roles of obesity and inflammation in AD pathogenesis with a
specific emphasis on women, who are disproportionately affected
by AD.
AD and Obesity
Obesity is a precursor condition for numerous disorders,
including cardiovascular disease, metabolic syndrome, and type
2 diabetes (T2D; Bonomini et al., 2015; Kim and Feldman,
2015). More recently, obesity and its associated comorbid
conditions have been identified as significant risk factors for
both cognitive decline and the development of AD (Jayaraman
and Pike, 2014). A growing literature suggests that the insulin
resistance and dysregulation of insulin signaling associated with
T2D are precursors to both cognitive impairment and AD
(Yaffe et al., 2004; Profenno et al., 2010). T2D in humans has
been shown to increase the rate of age-related mental decline
(Hassing et al., 2004), and those with T2D have been shown
to develop cognitive impairment earlier than those without this
risk factor (Cigolle et al., 2011). Further, adults with T2D have
a significantly increased risk of AD (Luchsinger et al., 2004;
Biessels et al., 2006; Profenno et al., 2010). Similarly, obesity
appears to significantly increase AD risk, particularly when it
is present during middle age (Kivipelto et al., 2005; Beydoun
et al., 2008; Fitzpatrick et al., 2009; Xu et al., 2011). In contrast
to most of the literature, a recent study with a very large sample
size reported that midlife obesity (measured as body mass index,
BMI) reduces dementia risk (Qizilbash et al., 2015). The absence
of concordance among several well-controlled studies suggests
that the relationship between obesity and AD is more complex
than simply an increase in adiposity. For example, some studies
suggest that dementia risk is not adversely affected by BMI per
se, but rather by central obesity specifically (Whitmer et al.,
2008; Gustafson et al., 2009; Luchsinger et al., 2012), which is
often closely associated with adverse health effects including
cardiovascular disease. In fact, cardiovascular outcomes are
predicted better by measures of central obesity and often poorly
by BMI (Yusuf et al., 2005; Dallongeville et al., 2012). Age is
also an important consideration, as obesity in late life appears
to reduce rather than increase AD risk (Fitzpatrick et al., 2009;
Gustafson et al., 2009). Collectively, these observations suggest
that central obesity in midlife induces changes that may create
a neural environment conducive to initial development of AD
pathology.
In general agreement with the human literature, experimental
studies in mouse models of AD demonstrate that diet-induced
obesity (DIO) significantly exacerbates AD-like neuropathology
and worsens cognitive impairment (Julien et al., 2010; Herculano
et al., 2013). Short-term high fat diet in an AD mouse model
was shown to cause mild metabolic dysfunction and significant
cognitive impairment, although no changes were observed in
levels of Aβ, a key protein in AD pathogenesis (Herculano et al.,
2013). High fat and high sucrose diets have also been shown to
affect tau accumulation, processing and hyperphosphorylation
(Julien et al., 2010; Orr et al., 2014; Takalo et al., 2014). In
3× Tg-AD mice, longer-term administration of a high fat diet
(16 weeks) impaired cognitive performance in both male and
female mice (Barron et al., 2013). In line with the behavioral
deficits, bothmale and female 3× Tg-ADmice showed increased
Aβ burden in the hippocampus. Male and female non-transgenic
rodents both exhibit decreased cognitive performance after
exposure to high fat diet (Molteni et al., 2002; Farr et al., 2008;
Granholm et al., 2008). In some cases, male mice are more
vulnerable to diet-induced cognitive impairment (Hwang et al.,
2010). Since males typically exhibit significantly more robust
metabolic deficits in response to high-fat diets (Barron et al.,
2013), this may suggest that some aspects of obesity-induced
cognitive impairment are related to metabolic disturbances,
including insulin resistance. However, since even short-term
exposure (9 days) to diets high in fat (Murray et al., 2009) results
in impaired spatial memory in rats, more immediate effects of
diet must also contribute to cognitive deficits. Diets high in
sugars can also yield negative outcomes in AD mouse models
(Cao et al., 2007; Orr et al., 2014) and wild-type rats (Hsu et al.,
2015). Together, these studies show that exposure to obesity-
inducing diets results in both rapid and long-term neural changes
that impair cognitive performance and accelerate development of
AD-like pathology.
The mechanism(s) by which obesity increases AD risk and
cognitive deficits is unknown, although numerous possibilities
have been proposed (Jayaraman et al., 2014). One widely
discussed concept is that AD risk is linked with changes
in glucose metabolism and insulin signaling (Blázquez et al.,
2014; de la Monte and Tong, 2014). Consistent with this
position, a reduction in brain glucose metabolism has been
shown to be a preclinical symptom of AD (Mosconi, 2005).
This reduction appears to be associated with altered insulin
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signaling. In obese patients, insulin resistance results in an
elevated release of peripheral insulin, but insulin concentrations
in the brain are reduced, likely due to a decrease in
insulin transport across the BBB (Craft, 2007). Although
insulin levels are decreased centrally, the situation is further
exacerbated by altered insulin signaling in the brain that is
less effective than under normal conditions (Anthony et al.,
2006). Interestingly, intranasal administration of insulin has
been shown to improve hippocampal dependent memory in
patients with early stages of AD (Reger et al., 2008; Claxton
et al., 2015). Perhaps in contrast to these observations, DIO
in female 3 × Tg-AD mice accelerated Aβ accumulation and
behavioral impairment in the absence of apparent changes in
peripheral insulin levels and sensitivity (Barron et al., 2013).
Collectively, these data suggest that obesity-induced insulin
resistance and/or impaired insulin signaling can contribute
to AD neuropathology although additional factors also play
significant roles.
Other than insulin-related deficits induced by obesity,
increased adiposity has other systemic effects that may
contribute to induction and progression of AD. For example,
increased adiposity elevates neuroinflammation (Thaler and
Schwartz, 2010; Thaler et al., 2012; Jayaraman et al., 2014;
Aguilar-Valles et al., 2015), which has been implicated as a
pathologic mechanism in AD (Johnston et al., 2011; Verri
et al., 2012; Wyss-Coray and Rogers, 2012). Systemic and
central inflammation will be discussed in greater detail below.
However, cerebrovascular inflammation in particular has
been widely associated with both obesity (Tucsek et al.,
2014) and AD (Yu et al., 2012; Takeda et al., 2013). In fact,
vascular inflammation may precede AD, as a transgenic
rodent model of obesity and AD showed cerebrovascular
inflammation and cognitive deficits prior to the deposition
of Aβ (Takeda et al., 2010). In this model, cerebral amyloid
angiopathy was much greater in obese animals compared
to lean ones. Other vascular risk factors that are associated
with obesity, including hyperlipidemia and hypertension,
have also been identified as AD risk factors (Kivipelto
et al., 2005). Thus, the mechanisms by which obesity
increases AD risk are presumably multifactorial and likely
modulated by a constellation of interactive risk factors and
comorbidities.
AD and Inflammation
Although inflammation has been implicated in AD pathogenesis
for many years, the importance of its role has been increasingly
appreciated in the past few years. As has been discussed in
other recent reviews (Mandrekar-Colucci and Landreth, 2010;
Wyss-Coray and Rogers, 2012), multiple lines of evidence link
inflammation as a key contributor to both the initiation and
progression of AD and identify it as a compelling therapeutic
target. Much of the recent focus on inflammation comes from
the linkage to AD of polymorphisms in genes that are expressed
by microglia and or play a role in innate immune responses
(Tanzi, 2012). Included in this list are CD33 (Bertram et al.,
2008; Hollingworth et al., 2011; Naj et al., 2011) and triggering
receptor expressed on myeloid cells 2 (TREM2; Leavy, 2015),
which are expressed in microglia and contribute to phagocytosis
and Aβ clearance. Other immune-related factors linked to AD
are CR1 and clusterin (Harold et al., 2009; Lambert et al., 2009),
components of the complement system.
Microglia are the key mediators of neuroinflammation,
functioning as the brain’s resident macrophages. In their role as
brain immune sentinels, microglia constantly survey the neural
environment for both normal and pathological disruptions. In
their normal state, microglia are clearly beneficial, utilizing
phagocytosis to remove unwanted or unneeded materials and
to regulate homeostatic processes such as synaptic remodeling
(Chen and Trapp, 2015). Further, they may have important
neurotrophic roles as suggested by their secretion of brain-
derived neurotrophic factor and insulin-like growth factor 1
(Parkhurst et al., 2013; Suh et al., 2013). When activated
under more pathological conditions, microglia exhibit a wide
range of responses that continue to be defined (Colton, 2009).
Among these responses, microglia alter their phagocytic activities
and can secrete large amounts of pro-inflammatory cytokines.
Cytokine secretion can be aggravated when microglia are
primed by an initial activating insult (Teeling and Perry,
2009). This type of priming response may contribute to
interactions among comorbid conditions such as obesity.
In this case, a high fat diet that results in obesity may
represent the first hit on the microglia and Aβ accumulation
the second, yielding an exaggerated response that may drive
pathology.
The AD brain is characterized by extensive gliosis, including
activation and increased numbers of both astrocytes and
microglia as well as elevated levels of inflammatory cytokines. Aβ
plaques, once formed, are rapidly (within 1–2 days) surrounded
by microglia (Meyer-Luehmann et al., 2008). Aβ has been shown
to promote the release of inflammatory cytokines frommicroglia
(Wyss-Coray and Rogers, 2012). Interestingly, increased pro-
inflammatory factors can result in greater amyloid precursor
protein production, leading to even more Aβ release and creating
a vicious cycle that further promotes AD pathology (Karran et al.,
2011). This progression of pathology appears to yield multiple
states of microglial activation and deactivation that presumably
vary in their effects on discrete AD pathologies (Colton, 2009).
For example, initial exposures of microglia to Aβ, while the
microglia are in their resting anti-inflammatory state, can result
in effective Aβ clearance. However, this insult induces an
activation state associated with the release of pro-inflammatory
cytokines like tumor necrosis factor α (TNFα) and interleukin
1β (IL-1β). After microglia achieve a pro-inflammatory state,
they may be less able to effectively phagocytose extracellular
Aβ (Koenigsknecht-Talboo and Landreth, 2005). Similarly,
microglia in an AD mouse model mice were shown to be
anti-inflammatory early in the disease, but to be activated
later after the pathology had progressed (Jimenez et al.,
2008).
Obesity and Inflammation
It has been more than two decades since the link between
inflammation and insulin resistance was first shown with an
increase in TNFα levels in obese rodents (Hotamisligil et al.,
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1993). Confirming an active rather than passive role in pathology,
neutralization of TNFα in obese rats resulted in a restored
response to insulin. This and other early studies spawned
intense study on the role of numerous inflammatory factors
in obesity, metabolic syndrome, and T2D. It is now clear that
not only is chronic low grade inflammation a symptom of
metabolic disorders, but also that both peripheral (Hotamisligil,
2006) and central (Thaler and Schwartz, 2010) inflammation
contribute to the development and progression of obesity and its
comorbidities.
Visceral fat, also known as central or abdominal fat, is thought
to have the greatest correlation with metabolic dysfunction
(Kissebah et al., 1982; Nieves et al., 2003). An increase in
body weight results in a corresponding increase in the number
of mature macrophages found in adipose tissue. Macrophages
invade and surround necrotic adipocytes and secrete excess
pro- and anti-inflammatory cytokines, including TNFα and
interleukin 6 (IL-6). The release of proinflammatory cytokines by
macrophages is thought to contribute to the glucose disruptions
and insulin resistance that is seen in obese individuals. Indeed,
if macrophages are specifically ablated, insulin and glucose
homeostasis can be rapidly restored and levels of inflammatory
cytokines in adipose tissue, muscle and serum reduced (Patsouris
et al., 2008). Further, adipocytes themselves secrete leptin and
IL-6 after the macrophage infiltration and further increase the
inflammatory response due in obesity. Adipose tissue is a highly
active immunological organ that contributes to the increased
inflammatory response to weight gain.
The role of inflammation in obesity also includes key
contributions from the brain. Obesity-induced increases in
peripheral and circulating cytokine levels likely affect the brain in
multiple ways. However, available evidence suggests that central
inflammation begins prior to the onset of obesity and appears
to contribute to the process (Thaler et al., 2013). Much of the
data on central inflammation and obesity has been generated
from DIO paradigms, in which increased adiposity results from
maintaining rodents on high-fat diets. DIO recapitulates much
of the human obesity condition and can be modified to include
specialized fats and/or sugars. Rodent DIO models have shown
that both central and peripheral inflammation are induced with
high fat diet (De Souza et al., 2005; Milanski et al., 2009; Thaler
et al., 2012). Inflammation in the hypothalamus in response to
high fat diet occurs within hours and persists for a few days
before subsiding only to return after about 2 weeks (Thaler
et al., 2012). Peripheral inflammation takes longer to develop
and usually coincides with an increase in adipose tissue mass.
Interestingly, mice with IL-1β, IL-6, or TNFα receptor knocked
out show a worsening rather than a reduction in both obesity
andmetabolic syndrome, suggesting that inflammation is not the
only contributing factor to these afflictions.
Inflammatory cytokines, which are elevated by obesity in both
adipose tissue and brain, appear to be involved in both promoting
inflammation and mediating many of its deleterious effects. In
the hypothalamus, DIO induces inflammation within 3 days of
the initiation of high fat diet in rodent (Thaler et al., 2012). Short-
term high fat diet results in an upregulation of activatedmicroglia
and astrocytes. In humans, increased gliosis that is similar to that
characteristic of injury is seen in the medial basal hypothalamus
of obese patients (Thaler et al., 2012). Consistent with their role
in adverse neural outcomes, cortical glia cultured from obese
mice retain their inflammatory phenotype and impair neuron
survival and growth in vitro (Jayaraman et al., 2014). Numerous
inflammatory factors have been shown to be upregulated by
obesity, including IL-1β, IL-6, TNFα and interleukin 18 (IL-18;
Vandanmagsar et al., 2011), but which ones are central the
relationship between obesity and AD are unclear. Here, we
consider a few of the factors that are affected by obesity with an
emphasis on those that also have been implicated in AD.
Leptin
Leptin is an adipokine that modulates appetite and informs the
brain about the availability of stored energy. Although leptin is
thought of as a peptide hormone, it bears remarkable similarity to
inflammatory cytokines, especially interleukin 2 (IL-2). Further,
the leptin receptor is homologous to the type 1 cytokine
receptors. Leptin secretion increases with increasing adiposity
(Considine et al., 1996). In the hypothalamus, leptin regulates
appetite. High levels of leptin normally induce satiety. However,
obese individuals develop leptin resistance, attenuating its ability
to properly regulate appetite. The increase in adipose tissue in
obese individuals initially results in elevated leptin release, but
the response to leptin is blunted and the satiety signal is not
recognized. The mechanisms that underlie leptin resistance have
not been fully elucidated, but it may be the result of disrupted
leptin signaling pathways, decreased leptin transport across the
BBB, or increased inflammation in the hypothalamus (Park and
Ahima, 2015).
In addition to regulating appetite, leptin is a regulator of
inflammation and the immune system. Leptin regulates both
innate and adaptive immune responses and generally increases
levels of pro-inflammatory cytokines (Conde et al., 2014). Initial
evidence of this link emerged from the observation that mice
with deficiencies in leptin signaling (ob/ob or db/db) exhibit
impaired immune responses (Lord et al., 1998). On the other
hand, leptin exposure increases the proliferation and activation
of T lymphocytes and promotes a T helper 1 phenotype (Martín-
Romero et al., 2000). Similarly, leptin activates components
of the innate immune response. For example, leptin increases
activation of monocytes, including their production of cytokines
such as TNFα and IL-6 (Santos-Alvarez et al., 1999). Also, leptin
can induce the expression of nitric oxide and prostaglandin
estrogen 17β-estradiol (E2) in cultured macrophages (Raso et al.,
2002). With signaling capacity both peripherally and centrally
and release modulated by fat mass, leptin is well positioned
to function as a mediator of interactions between the brain
and peripheral inflammatory responses (Carlton et al., 2012),
particularly in the context of obesity (Aguilar-Valles et al., 2015).
Leptin resistance is predicted to foster AD pathogenesis
as normal leptin signaling is associated with reduced AD
risk. Persons with mild cognitive impairment or AD show
lower plasma levels of leptin than cognitively normal controls
(Johnston et al., 2014). Cerebrospinal fluid (CSF) leptin levels
can remain stable with progression to AD, but a reduction in
leptin signaling in hippocampus suggests AD is associated with
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attenuation of leptin actions (Maioli et al., 2015). Conversely, in
a prospective study, elevated leptin levels were associated with
greater cerebral brain volume and reduced dementia risk (Lieb
et al., 2009). In experimental AD models, leptin administration
has been shown to have therapeutic effects on both Aβ deposition
(Fewlass et al., 2004) and tau phosphorylation (Greco et al.,
2008). Such protective pathways may become dysfunctional in
the AD brain, where leptin levels are elevated but expression of
its receptor is downregulated (Bonda et al., 2014). Further, the
leptin receptor protein was found localized to neurons containing
neurofibrillary tangles and within plaques, a situation expected
to disrupt its signaling capability. Indeed, phosphorylation of
the leptin receptor, which is required for its activation, was
reduced when the leptin receptor was found in tangle-bearing
neurons (Bonda et al., 2014). Collectively, available data indicate
that a loss of beneficial leptin signaling can contribute to AD,
suggesting that leptin resistance may be a mechanism by which
obesity affects AD risk.
TNFα
TNFα appears to be produced exclusively by macrophages in
adipose tissue with no contribution from adipocytes (Weisberg
et al., 2003). Both TNFα protein and mRNA are robustly
upregulated in obesity, an increase that has been shown to
correlate with the development of insulin resistance (Hotamisligil
et al., 1995). An increase in abdominal adipose tissue in particular
has been shown to correlate with increased TNFα release (Tsigos
et al., 1999). After weight loss, a decrease in TNFα protein
in adipose tissue and a decrease in serum insulin is observed
(Hotamisligil et al., 1995).
The neural effects of TNFα, which is produced in brain
by neurons and glia, can be both desirable and detrimental.
Transiently elevated levels of TNFα are beneficial. For example,
TNFα can recruit astrocytes and microglia to sites of injury
and activate a glial response (Flynn et al., 2003). However,
TNFα also exerts negative effects on neural plasticity, such as
reducing levels of long-term potentiation (Beattie et al., 2002;
Ferguson et al., 2008). Increased TNFα is also thought to promote
AD pathogenesis. For instance, in vitro and in vivo evidence
indicate that TNFα increases Aβ levels by increasing expression
of BACE1, an enzyme that drives Aβ production (Yamamoto
et al., 2007). Further, TNFα has been shown to inhibit the
transport of Aβ out of the brain and into peripheral circulation
where it can be eliminated (López et al., 2008). TNFα-mediated
increases in Aβ can lead to a vicious cycle. Aβ not only increases
expression of TNFα (Meda et al., 1995; Akama and Van Eldik,
2000) but also is able to activate the TNFα receptor TNFRI, which
is upregulated in AD brains compared to normal controls (Li
et al., 2004; Cheng et al., 2010). Further, Aβ-induced generation
of TNFα is implicated in the neurotoxic effects of Aβ (Xie et al.,
2002). Conversely, reducing TNFα may be neuroprotective. For
example, TNFRI knockout in AD transgenic mice diminishes
AD-like neuropathology (He et al., 2007).
IL-6
Both adipocytes and macrophages can generate and secrete
IL-6 from adipose tissue. Greater adiposity results in increased
IL-6 secretion. Serum IL-6 concentrations have been positively
correlated with obesity, insulin resistance (Bastard et al.,
2000; Kern et al., 2001), T2D (Pradhan et al., 2001), and
cardiovascular disease (Plutzky, 2001). Multiple studies in both
mice and humans have linked IL-6 to T2D as the cytokine
with the strongest association with metabolic dysfunction (Kern
et al., 2001; Pradhan et al., 2001). Although IL-6 production
is associated with visceral fat (Fontana et al., 2007), the
relationship between IL-6 and obesity is not straightforward. For
example, IL-6 knockout mice develop obesity, elevated leptin,
and altered glucose homeostasis with aging (Wallenius et al.,
2002), suggesting that long-term IL-6 depletion can contribute
to metabolic dysfunction. IL-6 administered peripherally in
knockout mice, reduces body weight and leptin levels. However,
IL-6 treatment is also associated with deleterious effects in
several paradigms. For example, in mouse hepatocytes and a
human hepatocarcinoma model, IL-6 disrupts insulin signaling
by decreasing insulin’s ability to activate Akt, a critical part
of insulin’s modulation of downstream metabolic effects (Senn
et al., 2002).
As with several other pro-inflammatory cytokines, chronic
elevation of IL-6 results in negative neural consequences. Cross-
sectional and longitudinal data indicate that elevated plasma IL-6
in mid-life is associated with significant cognitive decline (Singh-
Manoux et al., 2014). Several IL-6 genetic variants have been
shown to significantly regulate AD risk (Papassotiropoulos et al.,
1999; Chen et al., 2012; Flex et al., 2014). IL-6 has consistently
been shown to be elevated in the brains, especially near Aβ
plaques, and in the CSF of AD patients (Bauer et al., 1991; Blum-
Degen et al., 1995). The astrogliosis and microgliosis triggered by
AD results in increased IL-6 release from both of these cell types
(Erta et al., 2012). IL-6 has been implicated in AD pathogenesis
through several different mechanisms. For example, cultured
cortical neurons show more damage when treated with both Aβ
and IL-6. Further, in cultured hippocampal neurons, IL-6 has
been shown to increase tau phosphorylation (Quintanilla et al.,
2004).
AD, Menopause and Hormone Therapy
Since women are disproportionately affected by AD, there
has been considerable interest in understanding differences
in estrogen across the lifespan associated with AD risk. One
approach to investigating this idea is to consider the effects
of pregnancies, which yield a net decrease in lifetime estrogen
exposure (Bernstein et al., 1985; Hankinson et al., 1995). Several
studies have shown that women who have birthed children are
more likely to suffer from cognitive impairment and AD than
nulliparous women (Ptok et al., 2002; McLay et al., 2003; Colucci
et al., 2006; Beeri et al., 2009). Men with or without children
show no change in AD risk, so the difference cannot be due to
environmental factors associated with child rearing (Ptok et al.,
2002). Nulliparous women are therefore seemingly protected
from cognitive decline by their greater lifetime exposure to
estrogens.
Another approach to address this issue is to consider the
potential effects of estrogen loss on AD risk. Most studies
have found that surgical menopause prior to the development
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of natural menopause significantly increases risks for cognitive
decline and AD (Rocca et al., 2007, 2011; Phung et al., 2010; Bove
et al., 2014). Conversely, oophorectomy after the age of natural
menopause does not appear to significantly alter AD risk (Rocca
et al., 2011; Imtiaz et al., 2014). The implication of these studies
is that early loss of sex steroid hormones can accelerate the
development of AD. However, although brain levels of estrogens
are lower in women with AD than age-matched women without
neurologic disease, this relationship has been reported for only
for women older than age 80 years (Yue et al., 2005; Rosario
et al., 2011). Thus, while low estrogen appears to be associated
with AD, the timing of this relationship with respect to disease
onset remains unsettled.
If the depletion of ovarian sex steroid hormones at menopause
is a risk factor for AD, then maintenance of hormones would be
predicted to reduce AD risk. Consistent with this idea, AD risk
has been reported to be lowest in postmenopausal women with
the highest endogenous E2 levels and greatest in those with low
E2 levels (Manly et al., 2000). Another approach is to consider
how AD risk is affected by treatment with estrogen-based HT.
Initial observational studies generally found significantly reduced
risk of AD in women with a history of hormone therapy
(HT) use (Henderson et al., 1994, 1996), findings that were
supported by subsequent prospective studies (Tang et al., 1996;
Kawas et al., 1997; Zandi et al., 2002). Human studies have
been mirrored by experiments in transgenic mouse models of
AD, in which ovariectomy (OVX) induced loss of sex steroid
hormones increases and treatment with E2 generally reduces
AD-like neuropathology (Zheng et al., 2002; Yue et al., 2005;
Carroll et al., 2007; Zhao et al., 2011).
Despite the apparent benefits of estrogen-based HT in
reducing AD risk, discrepant clinical findings have demonstrated
neural risks and questioned its benefits. Most importantly, results
of the Women’s Health Initiative (WHI), a large double-blinded,
placebo-controlled clinical trial, indicated increased rather than
reduced dementia in subjects randomized to HT treatment
(Shumaker et al., 2003, 2004). There are numerous factors that
may contribute to the discordance of estrogen’s benefits across
the many human and rodent paradigms, including formulation
of the treatment, continuous vs. discontinuous delivery, and
route of administration. Perhaps the most significant issue is
the timing of treatment, with initiation of HT near the onset
of menopause hypothesized to be critical for its neural efficacy
(Maki, 2006). In the WHI, the mean age of subjects was about 65
years old, many years past the average onset of menopause at age
51. Studies in which HT was initiated at or near menopause have
generally reported benefits rather than risks. For example, in a
Danish study in which middle aged women were randomized to
HT and placebo treatment groups, beneficial effects on cognitive
function were observed more than 10 years after the cessation
of the 2–3 year HT regimen (Bagger et al., 2005). This finding
suggests that using HT, even for a short time during menopause,
may have a positive effect on cognitionmuch later. Similar results
have been found for AD risk: HT is associated with decreased risk
if delivered near menopause but has no benefit or even increases
risk when started several years after menopause (Henderson
et al., 2005; Whitmer et al., 2011; Shao et al., 2012). More work
will be required to fully elucidate the relationship between HT
and AD risk, but emerging results seem to suggest that short-
term HT near menopause onset may offer a reasonable strategy
to impede development of dementia.
Efficacy of HT is also likely to bemodulated by genetic factors.
The most significant genetic risk factor for late-onset AD is the
ε4 allele of ApoE4. ApoE4 regulates lipid trafficking and may
play a role in the removal of Aβ from the brain (Näslund et al.,
1995; Leduc et al., 2011). HT may be differentially effective in
women based on their ApoE status. In mice, E2 is able to reduce
inflammatory markers in cultures from ApoE3, but not ApoE4
mice (Brown et al., 2008). One study showed that HT around
menopause is more effective in preventing cognitive decline in
ApoE4-negative women than those with even a single ApoE4
allele (Yaffe et al., 2000). Further, the ApoE4 genotype may
increase the risk of AD more in females than males (Farrer et al.,
1997; Bretsky et al., 1999). Increased AD risk in ApoE4 carriers
requires only one ApoE4 allele in females with no further risk
increase in homozygotes, whereas significant male risk appears
to require two ApoE4 copies (Payami et al., 1996). A more
recent study showed that both male and female ApoE4 carriers
were at greater risk of AD with even one ApoE4 allele, but that
the risk for female carriers was significantly greater (Altmann
et al., 2014). How interactions between ApoE, HT and AD are
modulated by obesity, inflammation, and other factors that drive
AD pathogenesis remains to be determined.
Menopause and Adiposity
The shift from young adulthood into middle age is associated
with increasing proportions of women that are overweight
and/or obese (Ogden et al., 2014). This weight gain likely
reflects multifaceted consequences of aging. There is evidence
that depletion of sex steroid hormones during menopause can
contribute to weight gain, although body weight also predicts
subsequent changes in hormone levels (Guthrie et al., 1999;
Sternfeld et al., 2004; Wildman et al., 2012). Significant increases
in central fat have been reported with greater waist circumference
after the last menstrual period (Poehlman et al., 1995; Björkelund
et al., 1996; Ho et al., 2010). This increase in adiposity associated
with menopause is linked with increased risks for obesity
(Rachon´ and Teede, 2010), metabolic syndrome (Carr, 2003; Cho
et al., 2008) and T2D (Wajchenberg, 2000). Although increasing
age may partially account for the increase T2D incidence in
postmenopausal women (Janssen et al., 2008), the change in
fat distribution has also been shown to be a contributing cause
(Barrett-Connor et al., 1996; Tchernof et al., 1998; Sites et al.,
2000).
Studies in both humans (menopause) and rodents
(reproductive senescence) indicate that age-related ovarian
hormone loss contributes to changes in the distribution
of adipose tissue. The significant decrease in estrogen and
progesterone that results from follicular depletion yields a more
androgenic pattern of fat distribution—an increase in central
or abdominal adiposity. OVX in mice, a model of surgical
menopause, can result in a significant increase in body weight
(Stubbins et al., 2012). This elevated weight results from a
decrease in energy expenditure, as opposed to increases in
Frontiers in Aging Neuroscience | www.frontiersin.org 6 July 2015 | Volume 7 | Article 130
Christensen and Pike Menopause, obesity and inflammation
calorie consumption, and promotes insulin resistance, increased
adipocyte size, and peripheral inflammation (Rogers et al., 2009).
Treatment of mice with the E2 results in reductions in all of these
outcomes.
In postmenopausal women, estrogen-based HT has been
shown to decrease some of these metabolic effects in addition
to restoring a more gynoid pattern of fat distribution (Barrett-
Connor et al., 1996; Salpeter et al., 2006). HT can attenuate
central adiposity when administered to early postmenopausal
women (Haarbo et al., 1991; Ahtiainen et al., 2012). Additionally,
HT may decrease total weight gain during menopause, especially
in non-obese women (Kristensen et al., 1999). Further, HT
has been shown to increase the effectiveness of concurrent
lifestyle and pharmaceutical treatments for some obesity-related
comorbidities (Golden et al., 2013).
The mechanisms by which E2 reduces obesity and risk
of T2D remain to be fully elucidated. Paradoxically, risk of
maternal insulin resistance is highest in late pregnancy when
E2 levels are high (Ryan and Enns, 1988), yet low E2 levels
after menopause have been linked with T2D (Carr, 2003; Meyer
et al., 2011). Aromatase knockout mice, which cannot synthesize
E2, are obese and insulin resistant (Jones et al., 2000). Estrogen
receptor α (ERα) is likely to play a role in regulation of obesity
as ERα knockout mice are more obese and glucose intolerant
than wild-type females (Heine et al., 2000; Bryzgalova et al.,
2006). Further, both peripheral and central E2 administrations
have been shown to act through different pathways with
similar overall outcomes of reductions in insulin resistance,
glucose dysregulation and adiposity (Yonezawa et al., 2012).
Peripheral and central E2 administration resulted in decreased
adipocyte size and reduced expression of macrophage markers,
although peripheral E2 treatment elicited greater changes. Only
peripheral E2 administration decreased adipose expression of
the pro-inflammatory cytokine TNFα. Central and peripheral E2
administration both increased energy expenditure, but central
E2 caused much greater spontaneous locomotor activity. Thus,
E2 likely regulates adiposity and metabolic outcomes by actions
on several tissues. How these actions are affected by aging likely
underlies the interactions between menopause, obesity and the
efficacy of HT.
Inflammation and Menopause
There are extensive literatures on the relationships between
estrogens and other sex steroid hormones and regulation
of inflammation. In general, one can reasonably argue that
estrogens function as potent anti-inflammatory factors. Thus,
depletion of E2 at menopause results in elevated pro-
inflammatory cytokines and may place tissues throughout the
body at increased risk of inflammation and diseases associated
with inflammation (Pfeilschifter et al., 2002). However, this is
an extensive and complex literature as estrogens regulate several
aspects of immune function and inflammation (Straub, 2007)
and thus can protect against some conditions but promote
others (Gilliver, 2010). The relationships between estrogens,
menopause, and inflammation-related disorders have been well
described in numerous reviews for several conditions, including
cardiovascular disease (Camilleri et al., 2012; Knowlton and
Lee, 2012), osteoarthritis (Martín-Millán and Castañeda, 2013),
and rheumatoid arthritis (Islander et al., 2011). Thus, although
estrogens can be broadly defined as anti-inflammatory, the
effects of estrogen loss and estrogen-based HT depend upon the
tissue, cell type, and context.
Howmenopause affects neuroinflammation has not been well
studied. However, as with other tissues, the brain exhibits a
generally pro-inflammatory phenotype with increasing age. In
a study that examined changes in gene expression across age in
adult human brain, male and female brains exhibited significant
differences in the number of genes changing expression (higher
in males), the patterns of changes in terms of gene function,
and the brain region-specific nature of the changes (Berchtold
et al., 2008). Of particular interest to the current topic, women
exhibited greater proportional age-related increases in expression
of genes associated with immune and inflammatory functions.
Further, both women and men showed increased expression
of these genes in hippocampus and entorhinal cortex (both
of which are strongly affected in AD), but only women had
significant increases in other brain regions (Berchtold et al.,
2008), suggesting a more global pro-inflammatory condition in
the aging female brain.
Like the human brain, the rodent female brain shows
increased inflammation with aging that is regulated, in part, by
estrogen status. For example, the frontal cortex of middle-aged
female rats shows increased expression of several microglial
and immune function genes as a consequence of both aging
and estrogen-deprivation (Sárvári et al., 2012). Importantly,
the authors also found a strongly overlapping pattern of gene
expression changes in the frontal cortex of older postmenopausal
women relative to younger premenopausal women. Confirming
a protective role of estrogens, treatment of OVX middle-aged
rats with E2 or ER-specific agonists significantly decreased
expression of several microglial and immune function genes
in the frontal cortex (Sárvári et al., 2011). This relationship
extends to pro-inflammatory cytokines such as TNFα and IL-1β,
which show increased hippocampal expression in female mice
as consequences of both aging and OVX-induced estrogen
depletion (Benedusi et al., 2012). The age-related increase in
the pro-inflammatory state of the brain can be exacerbated
by inflammatory challenges. For example, the increased
hippocampal expression of cytokines induced by high cholesterol
diet is significantly worsened in reproductively senescent female
rats, an effect that can be attenuated by estradiol treatment (Lewis
et al., 2010). However, the ability of E2 to protect against elevated
cytokine levels can significantly diminish, and in some cases
reverse, in aged female brain (Nordell et al., 2003). Collectively,
these observations indicate that both aging and menopause
contribute to increasing levels of neuroinflammation, which
are predicted to cooperatively interact in the promotion of
inflammation neural diseases such as AD.
Conclusion
AD neuropathology is characterized and likely driven by
the accumulation of Aβ and abnormally phosphorylated tau.
The development of these and other components of AD
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FIGURE 1 | Alzheimer’s disease (AD) is a multifactorial disorder in
which multiple risk factors are theorized to interact in regulating
pathogenesis. As depicted in the diagram an essential factor in AD is
increasing age, which is also associated with elevated inflammation and, in
women, menopause. The loss of estrogens at menopause increases central
adiposity, which in turn increases inflammation and predisposes women to
metabolic syndrome, insulin resistance, and AD. Individually and cooperatively,
aging, menopause, adiposity, and inflammation lead to cognitive deficits
and AD.
neuropathology result from the interactive effects of several
risk factors (Figure 1). Most importantly, AD is dependent
upon aging. The negative outcomes of all genetic and
environmental risk factors of AD require advancing age. In
women, chronological aging is also tied to reproductive aging
that is manifested as menopause in mid-life. Menopause results
in cessation of the ovarian cycle and its cyclical production
of estrogens and progesterone, sex steroid hormones with
numerous protective roles against AD (Pike et al., 2009). Beyond
protective actions against specific aspects of AD neuropathology,
estrogens function throughout the body to guard against the
development of increasing central adiposity and inflammation,
both of which are implicated in the initiation and progression
of AD. Of course, aging is also associated with significant
increases in inflammation and central obesity, independent of
estrogen levels. Thus, women are simultaneously exposed to
the consequences of both chronological and reproductive aging,
both of which can function as drivers of AD, obesity, and
inflammation.
Estrogen-based HT initiated prior to the end of menopause
has been shown to be effective in combating both the increased
adiposity and the cognitive decline associated with aging.
Although HT can exhibit adverse side effects, especially in those
women who may be predisposed, emerging results suggest that
relatively short-term HT initiated near the onset of menopause
is likely to yield largely beneficial effects for most women.
Much more research will need to be done to determine
precisely which genetic or environmental factors define the target
population.
Inflammation is another seemingly invariant consequence of
aging. In females, inflammation is further increased by the loss of
estrogens atmenopause. As withmany other age-related diseases,
AD is linked with elevated inflammation during aging by
abundant data from several fields. Several specific inflammatory
factors have been linked to both obesity and AD including
leptin, TNF-α and IL-6. Since estrogens protect against both
the development and deleterious consequences of inflammation
across many tissues, depletion of estrogens at menopause is
theorized to contribute to women’s vulnerability to AD. Age-
related increases in adiposity and changes in the distribution of
fat to central depots further increase the risk of obesity, which
promotes downstream conditions including insulin resistance,
metabolic syndrome and T2D. Thus, a highly interactive set
of relationships develops in women: the cumulative effects
of aging, menopause, adiposity, and inflammation result in
increased risk for neural dysfunction and AD pathogenesis
(Figure 1). Certainly this set of factors is incomplete, as
new data continue to identify additional factors, including
bioenergetics, that not only are altered during reproductive
aging but also can promote AD (Yin et al., 2015). Continued
research is needed to address many unresolved issues about these
pathological interactions, including how they are modified by
genetic risk factors such as Apolipoprotein E (ApoE) and the
extent to which they can be effectively attenuated by estrogen-
based HT.
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